Broad Spectrum AI Designed Antibiotics for AMR

AINovo has used our proprietary AI platform to design novel biologic therapeutics which show broad-spectrum activity against clinical strains of AMR pathogens.

AI-designed molecules show broad spectrum activity for AMR Pathogens in vitro, synergy with existing antibiotics, variety of formulations possible

  • Antimicrobial compound/strategy

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human

Development stage:
  • Research
  • Development

  • Company

  • License, Co-develop

Funding organisation:
  • OTHER / NA

Infectious disease area:
  • BSI
  • RTI
  • SSTI
  • SSI

Geographic origin:
  • North America

AINovo has developed a proprietary artificial intelligence platform to design protein-based medicines &diagnostics for oncology & infectious diseases.

Partnerships with biopharma and research institutions for further development of our AMR assets, Technology-based partnerships with biopharma for joint development of novel molecules through AINovo Biotech’s artificial intelligence platform

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!